itstargetnews
timeSF local time
About It’s coming
It’s coming (HKEX: 9926.HK) is a leading biopharmaceutical company committed to the research, development, manufacturing and commercialization of first-in-class or best-in-class novel biological medicines. Founded in 2012, the company has created a unique integrated R&D innovation system with a comprehensive end-to-end drug development platform (ACE Platform) and bi-specific antibody drug development technology (Tetrabody) as the core, a GMP-compliant manufacturing system. and a commercialization system with an advanced mode of operation, and is gradually becoming a globally competitive biopharmaceutical company focused on innovative solutions. With a fully integrated multi-functional platform, It’s coming working within a robust pipeline of over 50 new properties in the fields of cancer, autoimmune disease, inflammation, metabolic disease and other major diseases. Among them, 22 candidates have entered clinical trials (including 11 bispecific/multispecific antibodies and bispecific antibody-drug conjugates). In addition, 5 new drugs are commercially available, and 5 new drugs in 7 indications are currently under regulatory review for approval. Through efficient and breakthrough R&D innovation, It’s coming constantly combines the world’s best resources, develops first-in-class and best-in-class new drugs, provides affordable therapeutic antibodies for patients around the world, and continues to create added commercial and social values to become a global leading biopharmaceutical business.
For more information, please visit https://www.akesobio.com/en/about-us/corporate-profile/ and follow us on LinkedInand X.
